FAAH/MAGL-IN-4（Cat No.:I011602）is a dual inhibitor targeting two key enzymes in the endocannabinoid system: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). FAAH metabolizes endocannabinoids like anandamide, while MAGL degrades 2-arachidonoylglycerol (2-AG). By inhibiting both enzymes, FAAH/MAGL-IN-4 increases the levels of these endocannabinoids, potentially enhancing their therapeutic effects on pain, inflammation, mood disorders, and neurodegenerative diseases. This compound is being explored for its ability to modulate the endocannabinoid system in a more comprehensive manner, offering a promising strategy for the treatment of conditions associated with dysregulated endocannabinoid signaling.